Return on investment of the lymphoma diagnostic pathway implementation in Alberta, Canada

The Lymphoma Diagnostic Pathway (LDP) was developed based upon clinical best practice guidelines and implemented in large urban centers where lymphoma treatment is provided in Alberta, Canada. A return-on-investment analysis of the implementation of this care pathway was conducted to inform future s...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-9
Main Authors: Waye, Arianna, Thanh, Nguyen X., Buckland, Tim, Scott, Allison N., Owen, Carolyn, Stewart, Douglas A.
Format: Article
Language:English
Subjects:
Alberta - epidemiology
Cost-Benefit Analysis
diagnosis
Humans
Lymphoma
return on investment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Lymphoma Diagnostic Pathway (LDP) was developed based upon clinical best practice guidelines and implemented in large urban centers where lymphoma treatment is provided in Alberta, Canada. A return-on-investment analysis of the implementation of this care pathway was conducted to inform future sustainability and expansion. A cohort design with propensity score matching and difference-in-difference estimation methods were used comparing both cost and return (reduced health service utilization) between patients who were diagnosed within the LDP and those who were diagnosed outside the LDP. LDP resulted in $1800 avoided HSU costs per patient. The LDP has been found to be cost-saving with an ROI of 5.3 (ranging from 3.95-8.97) - for every $1 invested, LDP resulted in a $5.30 return for the health system due to capacity improvements in ED, inpatient, outpatient, and a reduction in GP service utilization. Further study of implementation including patient/provider satisfaction and uptake is recommended.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2023.2209232